RT Journal Article
T1 Therapeutic potential of melatonin counteracting chemotherapy-induced toxicity in breast cancer patients: a systematic review
A1 Ramos, Eva
A1 Egea, Javier
A1 López Muñoz, Francisco
A1 Gil Martin, Emilio
A1 Romero, Alejandro
K1 2302.06 Quimioterapia
AB The purpose of this systematic review is to provide an overview of the existing knowledge on the therapeutic potential of melatonin to counteract the undesirable effects of chemotherapy in breast cancer patients. To this aim, we summarized and critically reviewed preclinical- and clinical-related evidence according to the PRISMA guidelines. Additionally, we developed an extrapolation of melatonin doses in animal studies to the human equivalent doses (HEDs) for randomized clinical trials (RCTs) with breast cancer patients. For the revision, 341 primary records were screened, which were reduced to 8 selected RCTs that met the inclusion criteria. We assembled the evidence drawn from these studies by analyzing the remaining gaps and treatment efficacy and suggested future translational research and clinical trials. Overall, the selected RCTs allow us to conclude that melatonin combined with standard chemotherapy lines would derive, at least, a better quality of life for breast cancer patients. Moreover, regular doses of 20 mg/day seemed to increase partial response and 1-year survival rates. Accordingly, this systematic review leads us to draw attention to the need for more RCTs to provide a comprehensive view of the promising actions of melatonin in breast cancer and, given the safety profile of this molecule, adequate translational doses should be established in further RCTs.
PB Pharmaceutics
SN 19994923
YR 2023
FD 2023-05-30
LK http://hdl.handle.net/11093/5149
UL http://hdl.handle.net/11093/5149
LA eng
NO Pharmaceutics, 15(6): 1616 (2023)
DS Investigo
RD 13-oct-2024